metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
la/mBC - HER2 positive - 2nd Line (L2) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 2nd Line (L2)
versus trastuzumab emtansine
	trastuzumab deruxtecan
	DESTINY Breast03, 2022 N Engl J Med 2022 Mar 24;386(12):1143-1154. NCT03529110	RCT	la/mBC - HER2 positive - 2nd Line (L2)	trastuzumab deruxtecan	trastuzumab emtansine	patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane	-/-	some concern	suggested	suggested 45 % decrease in deaths (OS) suggested 72 % decrease in progression or deaths (PFS)
metastatic/advanced - breast cancer (mBC) metastatic/advanced - breast cancer (mBC)
versus chemotherapy
	trastuzumab deruxtecan
	DESTINY-Breast04, 2022 New England Journal of Medicine NCT03734029	RCT	metastatic/advanced - breast cancer (mBC)	trastuzumab deruxtecan	physician’s choice of chemotherapy	patients with HER2-low metastatic breast cancer who had received one or two previous lines of chemotherapy	373 / 184	some concern	conclusif	demonstrated 36 % decrease in deaths (OS) (PE) demonstrated 50 % decrease in progression or deaths (PFS) (PE)

Study

study type

Pathology

T1

T0

Patients

sample sizes

ROB

Results

RCT

la/mBC - HER2 positive - 2nd Line (L2)

trastuzumab deruxtecan

trastuzumab emtansine

patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane

-/-

RCT

metastatic/advanced - breast cancer (mBC)

trastuzumab deruxtecan

physician’s choice of chemotherapy

patients with HER2-low metastatic breast cancer who had received one or two previous lines of chemotherapy

373 / 184